immune repertoire sequencing
Adaptive Biotechnologies Gets IVDR Class C Certification for ClonoSeq Assay
The certification makes the ClonoSeq assay available to EU patients and enables Adaptive to process EU clinical trial samples in its US laboratory.
Adaptive Biotechnologies Q2 Revenues Drop 12 Percent as MRD Revenues Soar
The Seattle-based company saw 36 percent growth in its minimal residual disease business while making significant progress in curbing operating expenses.
Adaptive Biotechnologies Expects Growth From FDA Panel MRD Vote, Cuts Staff by 7 Percent in Q1
Premium
Q1 revenues grew 11 percent year over year, to $41.9 million from $37.6 million, slightly less than the 12 percent increase the company had anticipated.
The company's technology, initially developed at UT Southwestern, sequences sets of T cell receptors that make up what it calls functional units.
Adaptive Biotechnologies Q4 Revenues Fall 17 Percent Tempered by Increase in MRD Business
Seattle-based Adaptive booked $45.8 million in Q4 revenues, 67 percent of which came from its minimal residual disease business.
May 5, 2022
Feb 25, 2021
Feb 24, 2021
Adaptive Biotechnologies Q4 Revenues Rise 25 Percent
Nov 10, 2020